ArticleBiomaterials2015
Tissue engineering a surrogate niche for metastatic cancer cells.
Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 70 citations in OpenAlex.
- Attract to kill: Exploring the potential of motility trapping as a novel treatment strategy for high-grade gliomas.Neuro-oncology · 2026Review
- Employing a Combination of Chemoattractants to Trap Glioblastoma Cells in a Macroporous Hydrogel.Pharmaceutics · 2026Article
- Design Principles of an Engineered Metastatic Niche for Monitoring of Cancer Progression.Biotechnology and bioengineering · 2025Article
- Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics.Polymers · 2024Review
- Silk Bioconjugates: From Chemistry and Concept to Application.ACS biomaterials science & engineering · 2024Review
- An engineered niche delineates metastatic potential of breast cancer.Bioengineering & translational medicine · 2024Article
- A synthetic metastatic niche reveals antitumor neutrophils drive breast cancer metastatic dormancy in the lungs.Nature communications · 2023Article
- A BMP-2-triggered in vivo osteo-organoid for cell therapy.Science advances · 2023Article
- Nanostructured Biomaterials forCurrent opinion in biomedical engineering · 2021Article
- Multicellular 3D Models to Study Tumour-Stroma Interactions.International journal of molecular sciences · 2021Review
- Breast Cancer Cells Metastasize to the Tissue-Engineered Premetastatic Niche by Using an Osteoid-Formed Polycaprolactone/Nanohydroxyapatite Scaffold.Computational and mathematical methods in medicine · 2021Article
- Human and mouse bones physiologically integrate in a humanized mouse model while maintaining species-specific ultrastructure.Science advances · 2020Article
- Engineered Niches to Analyze Mechanisms of Metastasis and Guide Precision Medicine.Cancer research · 2020Review
- Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2020Review
- Microporous scaffolds loaded with immunomodulatory lentivirus to study the contribution of immune cell populations to tumor cell recruitment in vivo.Biotechnology and bioengineering · 2020Article
- Review
- Bioengineered models to study tumor dormancy.Journal of biological engineering · 2019Review
- Reversing the Tumor Target: Establishment of a Tumor Trap.Frontiers in pharmacology · 2019Review
- A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions.Journal of functional biomaterials · 2018Article
- Implantable pre-metastatic niches for the study of the microenvironmental regulation of disseminated human tumour cells.Nature biomedical engineering · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
In breast and prostate cancer patients, the bone marrow is a preferred site of metastasis. We hypothesized that we could use tissue-engineering strategies to lure metastasizing cancer cells to tissue-engineered bone marrow. First, we generated highly porous 3D silk scaffolds that were biocompatible and amenable to bone morphogenetic protein 2 functionalization. Control and functionalized silk scaffolds were subcutaneously implanted in mice and bone marrow development was followed. Only functionalized scaffolds developed cancellous bone and red bone marrow, which appeared as early as two weeks post-implantation and further developed over the 16-week study period. This tissue-engineered bone marrow microenvironment could be readily manipulated in situ to understand the biology of bone metastasis. To test the ability of functionalized scaffolds to serve as a surrogate niche for metastasis, human breast cancer cells were injected into the mammary fat pads of mice. The treatment of animals with scaffolds had no significant effect on primary tumor growth. However, extensive metastasis was observed in functionalized scaffolds, and the highest levels for scaffolds that were in situ manipulated with receptor activator of nuclear factor kappa-B ligand (RANKL). We also applied this tissue-engineered bone marrow model in a prostate cancer and experimental metastasis setting. In summary, we were able to use tissue-engineered bone marrow to serve as a target or "trap" for metastasizing cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.